Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Inclusion Criteria:
Exclusion Criteria:
Saint Stefan, 8511, Austria
Saint Ingbert-Oberwürzbach, 66386, Germany
Thiruvnanthapuram, Kerala 695033, India
Chandigarh, Punjab 160012, India
Cheras, Kuala Lumpur 56000, Malaysia
Bygdoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
Legnica, Lower Silesian Voivodeship 59-220, Poland
Warsaw, Masovian Voivodeship 00-416, Poland
Bygdoszcz, 85-796, Poland